KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Short term Debt (2023 - 2025)

Recursion Pharmaceuticals' Short term Debt history spans 3 years, with the latest figure at $9.1 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 7.91% year-over-year to $9.1 million; the TTM value through Dec 2025 reached $9.1 million, up 7.91%, while the annual FY2025 figure was $9.1 million, 7.91% up from the prior year.
  • Short term Debt reached $9.1 million in Q4 2025 per RXRX's latest filing, up from $8.9 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $9.1 million in Q4 2025 to a low of $41000.0 in Q4 2023.
  • Average Short term Debt over 3 years is $7.5 million, with a median of $8.5 million recorded in 2024.
  • Peak YoY movement for Short term Debt: soared 20448.78% in 2024, then grew 7.91% in 2025.
  • A 3-year view of Short term Debt shows it stood at $41000.0 in 2023, then skyrocketed by 20448.78% to $8.4 million in 2024, then grew by 7.91% to $9.1 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Short term Debt are $9.1 million (Q4 2025), $8.9 million (Q3 2025), and $8.8 million (Q2 2025).